Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record.

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

Open access
Sow, Samba O., Okoko, Brown J., Diallo, Aldiouma, Viviani, Simonetta, Borrow, Ray, Carlone, George, Tapia, Milagritos, Akinsola, Adebayo K., Arduin, Pascal, Findlow, Helen, Elie, Cheryl, Haidara, Fadima Cheick, Adegbola, Richard A., Diop, Doudou, Parulekar, Varsha, Chaumont, Julie, Martellet, Lionel, Diallo, Fatoumata, Idoko, Olubukola T., Tang, Yuxiao, Plikaytis, Brian D., Kulkarni, Prasad S., Marchetti, Elisa, LaForce, F. Marc, Preziosi, Marie-Pierre·2011·New England Journal of Medicine

Abstract

BACKGROUND: Group A meningococci are the source of major epidemics of meningitis in Africa. An affordable, highly immunogenic meningococcal A conjugate vaccine is needed. METHODS: We conducted two studies in Africa to evaluate a new MenA conjugate vaccine (PsA-TT). In study A, 601 children, 12 to 23 months of age, were randomly assigned to receive PsA-TT, a quadrivalent polysaccharide reference vaccine (PsACWY), or a control vaccine (Haemophilus influenzae type b conjugate vaccine [Hib-TT]). Ten months later, these children underwent another round of randomization within each group to receive a full dose of PsA-TT, a one-fifth dose of PsACWY, or a full dose of Hib-TT, with 589 of the original participants receiving a booster dose. In study B, 900 subjects between 2 and 29 years of age were randomly assigned to receive PsA-TT or PsACWY. Safety and reactogenicity were evaluated, and immunogenicity was assessed by measuring the activity of group A serum bactericidal antibody (SBA) with rabbit complement and performing an IgG group A-specific enzyme-linked immunosorbent assay. RESULTS: In study A, 96.0% of the subjects in the PsA-TT group and 63.7% of those in the PsACWY group had SBA titers that were at least four times as high as those at baseline; in study B, 78.2% of the subjects in the PsA-TT group and 46.2% of those in the PsACWY group had SBA titers that were at least four times as high as those at baseline. The geometric mean SBA titers in the PsA-TT groups in studies A and B were greater by factors of 16 and 3, respectively, than they were in the PsACWY groups (P<0.001). In study A, the PsA-TT group had higher antibody titers at week 40 than the PsACWY group and had obvious immunologic memory after receiving a polysaccharide booster vaccine. Safety profiles were similar across vaccine groups, although PsA-TT recipients were more likely than PsACWY recipients to have tenderness and induration at the vaccination site. Adverse events were consistent with age-specific morbidity in the study areas; no serious vaccine-related adverse events were reported. CONCLUSIONS: The PsA-TT vaccine elicited a stronger response to group A antibody than the PsACWY vaccine. (Funded by the Meningitis Vaccine Project through a grant from the Bill and Melinda Gates Foundation; Controlled-Trials.com numbers, ISRCTN78147026 and ISRCTN87739946.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1003812

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 178

Metadata

Authors
Sow, S. O., Okoko, B. J., Diallo, A., Viviani, S., Borrow, R., Carlone, G., Tapia, M., Akinsola, A. K., Arduin, P., Findlow, H., Elie, C., Haidara, F. C., Adegbola, R. A., Diop, D., Parulekar, V., Chaumont, J., Martellet, L., Diallo, F., Idoko, O. T., Tang, Y., Plikaytis, B. D., Kulkarni, P. S., Marchetti, E., LaForce, F. M., & Preziosi, M.-P.
Venue
New England Journal of Medicine
Published
2011-06-16
Volume
364
Issue
24
Pages
2293-2304
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2038976319
Cited by
178
References
0
FWCI
24.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans. https://app.cochat.ai/papers/10.1056/nejmoa1003812
The paper
Sow, S. O., Okoko, B. J., Diallo, A., Viviani, S., Borrow, R., Carlone, G., Tapia, M., Akinsola, A. K., Arduin, P., Findlow, H., Elie, C., Haidara, F. C., Adegbola, R. A., Diop, D., Parulekar, V., Chaumont, J., Martellet, L., Diallo, F., Idoko, O. T., . . . Preziosi, M.-P. (2011). Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1003812

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.